Peptide Intelligence

Modified fragment of hGH amino acids 176-191. Developed as a lipolytic agent mimicking GH's fat-metabolizing effects without affecting blood glucose or IGF-1. Phase 2 trials showed modest weight loss. Abandoned by developer but remains available in peptide form.

16-amino acid peptide encoded in mitochondrial 12S rRNA. Discovered by Pinchas Cohen (USC) in 2015. Regulates metabolic homeostasis via AMPK pathway. Improves insulin sensitivity, promotes fat oxidation. Exercise mimetic — skeletal muscle expression increases with physical activity.

FDA-approved GLP-1 receptor agonist for type 2 diabetes (Ozempic) and chronic weight management (Wegovy 2.4mg weekly). Mean 14.9-16.8% body weight loss in STEP trials.

First dual GIP/GLP-1 receptor agonist. Superior weight loss vs GLP-1 RAs alone. Up to 22.5% weight loss in SURMOUNT-1. Approved for T2DM (Mounjaro) and obesity (Zepbound).

15-AA synthetic peptide from human gastric juice protein. Strongest preclinical evidence for tissue healing: muscle, tendon, ligament, bone, gut, neuro. No RCTs yet.

Synthetic thymosin β4 fragment. Promotes angiogenesis, tissue repair, cell migration, reduces fibrosis. WADA banned. Popular in sports/bodybuilding.

43-AA endogenous peptide in most tissues. Promotes cell migration, angiogenesis, wound healing, anti-inflammatory. Not WADA banned. Engineered versions showing promise in diabetic wound healing.

FDA-approved for HSDD in premenopausal women. Works centrally (MC4R), not hormonally — unique mechanism vs PDE5 inhibitors or hormones.

Synthetic GHRH(1-29) with MPA modification. Stimulates pulsatile GH release. Often paired with Ipamorelin for synergistic effect. WADA banned.

Synthetic hexapeptide growth hormone secretagogue. Potent GH release stimulator — more potent than GHRP-6 in GH release but with moderate appetite stimulation. Does not significantly elevate cortisol or prolactin. WADA banned. Used in GH deficiency diagnosis and off-label for anti-aging.

Synthetic hexapeptide, one of the first GH secretagogues developed. Potent GH releaser with significant appetite stimulation. Elevates cortisol and prolactin more than other GHRPs. WADA banned. Strong hunger effect makes it useful for patients needing appetite stimulation alongside GH release.

Synthetic hexapeptide GH secretagogue, the most potent GHRP for GH release. Developed by Europeptides. Produces the largest GH pulse of any GHRP. Cardiac regenerative potential demonstrated in preclinical models. WADA banned. Significant cortisol and prolactin elevation with chronic use — limits long-term utility.

Selective ghrelin mimetic. Stimulates GH release without affecting cortisol or appetite as much as other GHRPs. Often paired with CJC-1295. WADA banned.

FDA-approved GHRH analog for HIV-associated lipodystrophy. Stimulates endogenous GH, reduces visceral adipose tissue ~15%. Off-label aesthetic body contouring potential.

Mixture of neurotrophic peptides and amino acids. Approved in Europe/Asia for stroke, dementia, TBI. Crosses BBB. Not FDA-approved but available through specialty pharmacies.

Synthetic heptapeptide developed at Institute of Molecular Genetics (Russia), combining tuftsin fragment (Thr-Lys-Pro-Arg) with a stabilization sequence. FDA-equivalent approved in Russia as nasal drops. Anxiolytic and nootropic. Stabilizes enkephalins, modulates IL-6, influences BDNF and GABA systems.

Synthetic heptapeptide (ACTH(4-10) analog) developed at Moscow State University. Approved in Russia for stroke, TBI, cognitive disorders, and optic nerve disease. Normalizes BDNF, enhances neuroplasticity, crosses BBB via intranasal delivery. One of the most studied nootropic peptides.

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson. Activates telomerase in human cells, extending replicable lifespan in vitro. Preclinical evidence for pineal epithalamin mimicry. Clinical studies show reduced mortality in elderly patients and improved melatonin regulation.

Follistatin is a potent myostatin (GDF-8) and activin inhibitor. Animal knockout models show dramatic muscle hypertrophy. Clinically used in muscular dystrophy trials. Binds and neutralizes myostatin → removes the 'brake' on muscle growth. Also inhibits activin → may affect reproductive hormones.

Modified IGF-1 with 13-amino acid extension (Long) and Arg substitution at position 3 (R3). 10x longer half-life than native IGF-1 (~20-30 hrs vs ~12 hrs). Reduced binding to IGFBPs → enhanced bioavailability. Promotes muscle growth, tissue repair, neuroprotection.

PEGylated form of Mechano Growth Factor (IGF-1Ec), a splice variant of IGF-1 expressed in response to mechanical stimulation. PEGylation extends half-life from minutes to ~48-72 hours. Promotes satellite cell activation and muscle repair. WADA banned.

Human plasma tripeptide (Gly-His-Lys) bound to copper 2+. Declines with age. Stimulates collagen, tightens skin, reduces wrinkles/fine lines, promotes wound healing. Topical and injectable forms.

Tripeptide (Ala-His-Lys) derived from laminin, a key basement membrane protein. Promotes cell adhesion, migration, and wound healing. Stimulates collagen I and III synthesis, upregulates integrin expression. Used in cosmetic formulations and wound healing applications. Mimics laminin's cell-binding domain.

28-AA peptide from thymosin fraction 5. Immune modulator. Approved in 30+ countries (not FDA-approved). Used for hepatitis B/C, immune support, cancer adjunct. Restores immune balance in liver failure.

Zinc-dependent nonapeptide produced by thymic epithelial cells. Essential for T-cell maturation and differentiation. Declines with age (thymic involution). Restores immune function in aged and immunocompromised models. Requires zinc for biological activity. Studied in autoimmune diseases and immune senescence.